Login
Companies $FLNA
$0.48 +$0.01 (2.13%) After hours
FILANA THERAPEUTICS, INC. logo

FILANA THERAPEUTICS, INC.

filanatx.com

What Do They Do?

Develops simufilam, an oral drug candidate for tuberous sclerosis complex-related epilepsy and other disorders associated with filamin A.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +1% (Loss)
vs −$10.8M in Q3 FY2025
  • Sep 22, 2026 FDA lifted the clinical hold on simufilam’s planned epilepsy study The company said patient screening is expected to begin by the first quarter of 2027.
  • Sep 17, 2026 Nasdaq notified the company it was below the minimum bid-price requirement The company had until March 16, 2027, to regain compliance; its shares continued to trade on Nasdaq.

A shift in disease focus The older report described simufilam as being studied for Alzheimer’s disease and also listed a blood test candidate for detecting Alzheimer’s. The latest report focuses on simufilam for TSC-related epilepsy and other conditions associated with filamin A.

Who Do They Compete With?

Competes with Vigabatrin, Levetiracetam, Valproate, Clobazam, Afinitor Disperz, and Epidiolex

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support